Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum C VGM
Zacks News
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Why Boston Scientific (BSX) Might Surprise This Earnings Season
by Zacks Equity Research
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
by Zacks Equity Research
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
The Zacks Analyst Blog Highlights: NIKE, Applied Materials, Square, Boston Scientific and Petrobras
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Applied Materials, Square, Boston Scientific and Petrobras
Top Research Reports for NIKE, Applied Materials & Square
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Applied Materials (AMAT), and Square (SQ).
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.
Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care
by Zacks Equity Research
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.
Boston Scientific (BSX) Hurt by Product Recall, Currency Woes
by Zacks Equity Research
Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.
Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC
by Zacks Equity Research
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific (BSX) Buys Lumenis to Expand in Urology
by Zacks Equity Research
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.
Boston Scientific (BSX) Hurt by Product Recall, Conversion
by Zacks Equity Research
Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
by Zacks Equity Research
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
Boston Scientific (BSX) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Skyworks (SWKS) & 3 Other Suppliers to Tap Uptick in iPhone Sales
by Radhika Pujara
Shares of Skyworks (SWKS) are skyrocketing post upbeat guidance and impressive Q1 performance driven by uptick in Apple's (AAPL) iPhone 12 sales. This positions other suppliers, including QRVO, JBL & SYNA, well to gain from the projected increase in iPhone 12 demand.
Skyworks' (SWKS) Q1 Earnings Top Estimates, Stock Up on Q2 View
by Zacks Equity Research
Skyworks' (SWKS) fiscal first-quarter results gain from rapid 5G deployment and strength in overall broad markets.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Boston Scientific's (BSX) DBS System Gets FDA's Clearance
by Zacks Equity Research
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Boston Scientific (BSX) Enhances Core Business With Buyout
by Zacks Equity Research
Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.